Norsko - norština - Statens legemiddelverk

fresenius - natriumklorid / natriumhydrogenkarbonat / kalsiumklorid / magnesiumkloridheksahydrat / glukosemonohydrat - hemodialyse-/hemofiltreringsvæske

Norsko - norština - Statens legemiddelverk

baxter holding b.v. - kalsiumkloriddihydrat / dinatriumfosfatdihydrat / magnesiumkloridheksahydrat / natriumklorid / natriumhydrogenkarbonat / kaliumklorid - hemodialyse-/hemofiltreringsvæske

Norsko - norština - Statens legemiddelverk

baxter holding b.v. - kalsiumkloriddihydrat / magnesiumkloridheksahydrat / glukosemonohydrat / melkesyre, (s)- / natriumklorid / kaliumklorid / natriumhydrogenkarbonat - hemodialyse-/hemofiltreringsvæske

Norsko - norština - Statens legemiddelverk

casen recordati, s.l - dinatriumfosfatdodekahydrat / natriumdihydrogenfosfatdihydrat - mikstur, oppløsning - 10.8 g/ dose / 24.4 g/ dose

Norsko - norština - Statens legemiddelverk

reckitt benckiser healthcare (scandinavia) a/s - natriumalginat / kalsiumkarbonat / natriumhydrogenkarbonat - mikstur, suspensjon i dosepose med peppermyntesmak - 500 mg / 325 mg / 213 mg

Norsko - norština - Statens legemiddelverk

b. braun melsungen ag - glukosemonohydrat / natriumdihydrogenfosfatdihydrat / sinkacetatdihydrat / soyaolje, renset / triglyserider av middels kjedelengde / isoleucin / leucin / lysinhydroklorid / metionin / fenylalanin / treonin / tryptofan / valin / arginin / histidinhydrokloridmonohydrat / alanin / aspartinsyre / glutaminsyre / glysin / prolin / serin / natriumhydroksid / natriumklorid / natriumacetattrihydrat / kaliumacetat / magnesiumacetattetrahydrat / kalsiumkloriddihydrat - infusjonsvæske, emulsjon - 64 mg/ ml / 0.936 mg/ ml / 0.0052 mg/ ml / 20 mg/ ml / 20 mg/ ml / 1.872 mg/ ml / 2.504 mg/ ml / 1.818 mg/ ml / 1.568 mg/ ml / 2.808 mg/ ml / 1.456 mg/ ml / 0.456 mg/ ml / 2.08 mg/ ml / 2.16 mg/ ml / 1 mg/ ml / 3.88 mg/ ml / 1.2 mg/ ml / 2.8 mg/ ml / 1.32 mg/ ml / 2.72 mg/ ml / 2.4 mg/ ml / 0.64 mg/ ml / 0.865 mg/ ml / 0.435 mg/ ml / 2.354 mg/ ml / 0.515 mg/ ml / 0.353 mg/ ml

Norsko - norština - Statens legemiddelverk

b. braun melsungen ag - glukosemonohydrat / natriumdihydrogenfosfatdihydrat / sinkacetatdihydrat / soyaolje, renset / triglyserider av middels kjedelengde / isoleucin / leucin / lysinhydroklorid / metionin / fenylalanin / treonin / tryptofan / valin / arginin / histidinhydrokloridmonohydrat / alanin / aspartinsyre / glutaminsyre / glysin / prolin / serin / natriumhydroksid / natriumklorid / natriumacetattrihydrat / kaliumacetat / magnesiumacetattetrahydrat / kalsiumkloriddihydrat - infusjonsvæske, emulsjon - 120 mg/ ml / 1.872 mg/ ml / 0.0052 mg/ ml / 20 mg/ ml / 20 mg/ ml / 2.256 mg/ ml / 3.008 mg/ ml / 2.184 mg/ ml / 1.88 mg/ ml / 3.368 mg/ ml / 1.744 mg/ ml / 0.544 mg/ ml / 2.496 mg/ ml / 2.592 mg/ ml / 1.202 mg/ ml / 4.656 mg/ ml / 1.44 mg/ ml / 3.368 mg/ ml / 1.584 mg/ ml / 3.264 mg/ ml / 2.88 mg/ ml / 0.781 mg/ ml / 0.402 mg/ ml / 0.222 mg/ ml / 2.747 mg/ ml / 0.686 mg/ ml / 0.47 mg/ ml

Norsko - norština - Statens legemiddelverk

b. braun melsungen ag - glukosemonohydrat / natriumdihydrogenfosfatdihydrat / sinkacetatdihydrat / soyaolje, renset / triglyserider av middels kjedelengde / isoleucin / leucin / lysinhydroklorid / metionin / fenylalanin / treonin / tryptofan / valin / arginin / histidinhydrokloridmonohydrat / alanin / aspartinsyre / glutaminsyre / glysin / prolin / serin / natriumhydroksid / natriumklorid / natriumacetattrihydrat / kaliumacetat / magnesiumacetattetrahydrat / kalsiumkloriddihydrat - infusjonsvæske, emulsjon - 144 mg/ ml / 2.496 mg/ ml / 0.007 mg/ ml / 20 mg/ ml / 20 mg/ ml / 3.284 mg/ ml / 4.384 mg/ ml / 3.186 mg/ ml / 2.736 mg/ ml / 4.916 mg/ ml / 2.54 mg/ ml / 0.8 mg/ ml / 3.604 mg/ ml / 3.78 mg/ ml / 1.753 mg/ ml / 6.792 mg/ ml / 2.1 mg/ ml / 4.908 mg/ ml / 2.312 mg/ ml / 4.76 mg/ ml / 4.2 mg/ ml / 1.171 mg/ ml / 0.378 mg/ ml / 0.25 mg/ ml / 3.689 mg/ ml / 0.91 mg/ ml / 0.623 mg/ ml

Evropská unie - norština - EMA (European Medicines Agency)

astellas pharma europe b.v. - enzalutamide - prostata neoplasmer - endokrin terapi - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.

Evropská unie - norština - EMA (European Medicines Agency)

bayer ag - darolutamide - prostatic neoplasmer, kastrering-resistant - endokrin terapi - nubeqa is indicated for the treatment of adult men with- non metastatic castration resistant prostate cancer (nmcrpc) who are at high risk of developing metastatic disease (see section 5. - metastatic hormone sensitive prostate cancer (mhspc) in combination with docetaxel and androgen deprivation therapy (see section 5.